Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía-León, Juan Antonio 
dc.contributor.authorCáceres Palomo, Laura
dc.contributor.authorTrujillo Estrada, Laura
dc.contributor.authorLópez Oliva, Elba
dc.contributor.authorVitorica Ferrández, Javier
dc.contributor.authorGutiérrez-Pérez, Antonia 
dc.date.accessioned2023-07-24T10:06:10Z
dc.date.available2023-07-24T10:06:10Z
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/10630/27362
dc.description.abstractAlzheimer's disease (AD) is characterized by presenting a complex pathology, not fully resolved yet. This fact, together with the lack of reliable models, has impeded the development of effective therapies. Recently, several studies have shown that functional glial cell defects have a key role in the pathology of AD. However, this glial dysfunction, currently, cannot be correctly modeled using the available animal models, so we hypothesized that cells derived from Alzheimer's patients can serve as a better platform for studying the disease. In this sense, human pluripotent stem cells (hPSC) allow the generation of different types of neural cells, which can be used for disease modeling, identification of new targets and drugs development. Methods: We have a collection of hiPSCs derived from patients with sporadic forms of AD stratified based on APOE genotype. We have differentiated these cells towards neural cells and mature them to neurons or astrocytes using a serum-free approach, to assess intrinsic differences between those derived from AD patients or healthy controls. Results: We have implemented a serum-free approach and generated neural precursors and astrocytes from all the lines tested. We observe differences at the phenotypic level and a reduced capacity to differentiate towards neural lineage in those lines derived from APOE4 carriers. Conclusions: Our preliminary data suggest intrinsic differences in the neural differentiation capacity between cell lines derived from APOE4 or APOE3 carrier subjects. Further experiments would contribute to elucidate novel pathogenic pathways associated with neurodegeneration and susceptible of therapeutic modulation, likely contributing to the development of new effective drugs against AD.es_ES
dc.description.sponsorshipThis study was supported by Instituto de Salud Carlos III (ISCiii) of Spain, co-financed by FEDER funds from European Union, through grants PI21/00915 (to AG) and PI21/00914 (to JV); by Junta de Andalucia through Consejería de Economía y Conocimiento grants UMA20-FEDERJA-048 (to JAGL), PY18-RT-2233 (to AG) and US-1262734 (to JV) co-financed by Programa Operativo FEDER 2014-2020, and Programa Operativo de Empleo Juvenil SNGJ4-11 to LCP. Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech.es_ES
dc.language.isoenges_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectAlzheimer, Enfermedad dees_ES
dc.subject.otheriPSCes_ES
dc.subject.otherAlzheimeres_ES
dc.subject.otherNeurodegenerationes_ES
dc.subject.otherInflammationes_ES
dc.subject.otherAstrocytees_ES
dc.titleGlia and neurons from human iPSCs to address the pathology of Alzheimer´s diseasees_ES
dc.typeinfo:eu-repo/semantics/conferenceObjectes_ES
dc.centroFacultad de Cienciases_ES
dc.relation.eventtitle16th European Meeting on Glial Cells in Health and Diseasees_ES
dc.relation.eventplaceBerlin, Alemaniaes_ES
dc.relation.eventdate07/07/2023es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem